
|Articles|April 1, 2003
Should a prostaglandin agent be used as initial monotherapy?
Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma medications in the world. Although timolol is considered to be the most significant therapeutic advance in the medical treatment of glaucoma in the 20th century, the 1994 introduction of prostaglandin analogs for glaucoma treatment in Japan marked the end of timolol's domination.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Why individualized glaucoma care remains essential amid uneven patient awareness
3
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
4
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
5














































